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E D I T O R I A L  
BIOMARKERS OF AGING 
CURRENTLY THERE is a great clamoring from vocal segments of the gerontological 
research community, as well as from public and private funding agencies, for bigger and 
better biomarker research in gerontology. The time has come to raise a precautionary, 
even dissenting voice. 
What is meant by the phrase, biomarkers of aging? In my experience, this phrase has 
different meanings to different people. Some regard it as a means to measure the degree 
of functional age as opposed to chronological age. Some regard it as a means to ascer- 
tain a rate of aging. Others regard it as a standard by which to assess the effectiveness of 
a therapeutic intervention. Still others regard it as a means to document successful 
aging. 
In my opinion, history will regard research related to the identification of such 
biomarkers of aging as no more than of fleeting significance. Sophisticated research 
entails so much more than pure empiricism. The significance of research on biomarkers 
of aging, in my opinion, will be reserved primarily for the identification, fundamental 
understanding, and ability to manipulate the expression of one or more steps of a 
genetically determined, developmental sequence of biological events which herald the 
onset of altered susceptibility to environmental challenge and, ultimately, death. In- 
deed, the seemingly endless passion for characterizing and modifying features of the 
elderly inevitably will give way to the pursuit of underlying mechanisms. 
Why is the practical significance of this latter approach so minimally addressed on the 
research agenda of the gerontological research community and that of relevant funding 
agencies? Why, just as cancer research passed through its long period of cure-testing 
and so forth, must gerontological research be doomed to repeat such mistakes? There is 
obvious value in the ability to distinguish between functional and chronological age. For 
example, why should an individual who loses one kind of mental and/or physical capa- 
bility, while retaining others, be disregarded wastefully? Similar kinds of arguments 
may be posed with compassion as they relate to relative rates of aging, to establishment 
of therapeutic interventions, and to hallmarks of successful aging. After all, even I 
desire for my loved ones and myself a successful aging that is free of disease, ripe with 
continued opportunity and productivity, and complete with assurances of dignity and 
respect. 
However, in a scholarly sense, such emotionally fashionable issues are both super- 
ficial and unsophisticated. Moreover, they tend to obscure the importance of gaining a 
basic understanding of the processes of aging. Continuous efforts to characterize de- 
scriptively, as well as to solve the problems of old age, at least in my opinion, should 
not take precedence over the pursuit of new knowledge regarding the mechanisms of 
aging. 
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Stop-gap measures may indeed have immediate impact. This is precisely why they 
are too often of such great appeal to the leadership of Congress, to certain public and 
private funding agencies, and to others untrained in basic science. However, in the long 
run such stop-gap measures only perpetuate the conditions they were intended to 
alleviate. 
What substantiation do I provide for my allegations of superficiality and lack of 
scholarly sophistication in current tendencies of biomarker research? In an effort to 
make my point, consider the following single specific example. Let us assume arbitrar- 
ily that high circulating levels of catecholamines represent one example of a biomarker 
of aging. 
Is it possible that the high circulating level of catecholamines during aging can be 
utilized either itself or as one of a battery of tests in order to distinguish between 
chronological and functional age of the experimental subjects? Is it possible that the 
high circulating level of catecholamines during aging can be utilized either itself or as 
one of a battery of tests, when detected in the same group of individuals at two or more 
different points in their lifespan, to ascertain a rate of aging? Is it possible that pertur- 
bation of the high circulating level of catecholamines during aging can be utilized either 
itself or as one of a battery of tests to assess the efficacy of a putative therapeutic 
regimen? Is it possible to interpret a successful therapeutic restoration of circulating 
levels of catecholamines in older people to levels which are more characteristic of 
younger people as successful intervention, thereby restoring the individuals in question 
to something approaching more successful aging? In my opinion, the correct answer to 
each of these questions is as follows. Yes, it certainly is possible, although highly 
unlikely. 
Why might circulating levels of catecholamines be higher in older individuals than in 
younger individuals? Let me identify only a few of the underlying mechanisms which 
conceivably might contribute to such a phenomenon of aging: 1) desensitization of 
catecholamine receptors on the cell membranes of target tissues; 2) diminished 
metabolic turnover of catecholamines; 3) enhanced biosynthesis and/or secretion of 
catecholamines; 4) one or more disease states to which the autonomic nervous system 
responds by a chronically enhanced outpouring of catecholamines; 5) reduced avail- 
ability of essential social support systems, thereby provoking a chronic stress response 
in the older individuals in question; 6) an age-associated personality change which 
manifests itself in part as a chronic stress response; 7) an age-associated increase in the 
distrust of the individuals who are responsible for physical measurement of the 
biomarker in question; etc., etc., etc. 
Given two older individuals of the identical chronological age, each with vastly 
different circulating levels of catecholamines, is one functionally older than the other? 
Is one aging more successfully than the other? Will a therapeutic intervention which 
successfully restores catecholamines to a lower circulating level in any manner alleviate 
the relevant pathology, personality change, unavailable social support, etc., etc., etc. ? I 
have great doubts! 
What might one constructively conclude from the foregoing? I have no intention 
whatsoever of attempting to criticize any kind of research, as long as the research is of 
high quality. To those of you who prefer to distinguish between functional and 
chronological age, to determine rates of aging, to establish successful therapeutic regi- 
mens, to characterize successful aging, that certainly is your prerogative as independ- 
ent investigators. 
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However, in my opinion the emphasis of gerontological research, as well as its 
ultimate societal impact, lies in a totally different direction. When, how and why aging 
begins are the more important questions. The power and beauty of basic science even- 
tually dominates the scene in every sophisticated research community. It is only a 
matter of time until the biomarker of maturation of the gerontological research com- 
munity will be identified as the inclination and ability of the majority of researchers and 
funding agencies alike to comprehend the significance and to emphasize tile pursuit of 
underlying mechanisms. Furthermore, it is a too often forgotten lesson of the history of 
science that the most significant societal advances usually result not by administrative 
design of the funding agencies, but instead, serendipitously from straightforward, non- 
targeted, investigator-initiated, high quality basic research. 
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